Key result
The 2008 PSA screening guideline change was associated with a decrease in the mean annual age-adjusted prostate cancer incidence rate from 157.7 in 2005-2008 to 131.9 per 100,000 men in 2009-2012.
Why the study?
It was unclear whether documented changes in prostate cancer incidence and stage distributions following the 2008 and 2012 USPSTF PSA screening guidelines were temporary or differed by age or race and ethnicity.
Do changes in PSA screening guidelines affect prostate cancer incidence rates across different age, race, and ethnicity groups?
Cross-Sectional (n=2,944,387)
Yes
Do changes in PSA screening guidelines affect prostate cancer incidence rates across different age, race, and ethnicity groups?
Absolute Event Rate: 131.9% vs 157.7%
Changes in PSA screening guidelines in 2008 and 2012 were associated with varying patterns of decreased prostate cancer incidence across different age, race, and ethnicity groups.
Declines in prostate cancer incidence after 2008 PSA guidelines may signal reduced overdiagnosis; leaves open whether impacts differ by age, race, and ethnicity.
Importance: After publication of US Preventive Task Force Prostate-Specific Antigen (PSA) screening guidelines in 2008 and 2012, there have been documented associations with incidence and stage distributions of prostate cancer. It is unclear if these changes were temporary or differed by age or race and ethnicity. Objective: To assess the association of 2008 and 2012 PSA guidelines with prostate cancer incidence by age and race and ethnicity in the US. Design, Setting, and Participants: This cross-sectional study evaluated prostate cancer incidence from 2005 to 2018 in the US using data from the US Cancer Statistics public use database. Data were analyzed from August 2020 through June 2022. Main Outcomes and Measures: The primary outcome was the year when rates of prostate cancer incidence changed directionality by age and race and ethnicity. Age-adjusted incidence rates of prostate cancer and corresponding 95% CIs were created, followed by join point regression analysis to evaluate trends of age-adjusted incidence rates of prostate cancer by age, race, Hispanic ethnicity, and stage of diagnosis. Results: Among 2 944 387 men with prostate cancer, 2 869 943 (97.5%) men were aged 50 years and older. Men aged 50 years and older accounted for 185 476 of 191 533 Hispanic individuals (96.8%) and 2 684 467 of 2 752 854 non-Hispanic individuals (97.5%). Men aged 50 years and older accounted for 427 016 of 447 847 African American individuals (95.4%), 12 141 of 12 470 American Indian or Alaska Native individuals (97.4%), 61 126 of 62 159 Asian or Pacific Islander individuals (98.3%), and 2 294 171 of 2 344 392 White individuals (97.9%). Men with unknown race (77 519 men) were excluded from the analysis. A decrease in age-adjusted rate of prostate cancer after the 2008 guideline change was observed in all age groups by race and ethnicity. For example, among African American men ages 65 to 74 years, 10 784 of 807 080 men (1.34%) had a prostate cancer diagnosis in 2007 vs 10 714 of 835 548 men in 2008 (1.28%). The mean annual age-adjusted incidence rates of prostate cancer per 100 000 men were 157.7 men (95% CI, 157.4-158.0 men) in 2005 to 2008 and 131.9 men (95% CI, 131.6-132.2 men) in 2009 to 2012. The number of inflections and annual percent changes (APCs) for segments separated by inflections varied by age, race, and Hispanic ethnicity. For men ages 65 to 74 years, the APC was -6.53 (95% CI, -9.28 to -3.69) for 2009 to 2014 among African American men (2 join points), -5.96 (95% CI, -6.84 to -5.07) for 2007 to 2018 among American Indian or Alaska Native men (1 join point), -6.52 (95% CI, -9.22 to -3.74) for 2007 to 2014 among Asian or Pacific Islander men (2 join points), -7.92 (95% CI, -11.36 to -4.35) for 2009 to 2014 among Hispanic men (2 join points), and -7.02 (95% CI, -9.41 to -4.57) for 2007 to 2014 among White men (2 join points).. Conclusions and Relevance: In this study, men in different age, race, and ethnicity groups had different APC patterns after 2008 and 2012 PSA screening guideline changes. These findings may provide important data on the timing and durations of changes in cancer diagnoses that are associated with changes in PSA screening recommendations and may be valuable for targeted strategies to reduce regional- and distant-staged cancers.
No takes yet. Share an insight, caveat, or question.
Lai et al. (2022) conducted a cross-sectional in Prostate cancer (n=2,944,387). 2008 and 2012 PSA screening guideline changes vs. Before guideline changes (2005-2008) was evaluated on Year when rates of prostate cancer incidence changed directionality by age and race and ethnicity. The 2008 PSA screening guideline change was associated with a decrease in the mean annual age-adjusted prostate cancer incidence rate from 157.7 in 2005-2008 to 131.9 per 100,000 men in 2009-2012.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: